Net profit of Vimta Labs rose 112.24% to Rs 21.50 crore in the quarter ended December 2024 as against Rs 10.13 crore during the previous quarter ended December 2023. Sales rose 20.57% to Rs 89.92 crore in the quarter ended December 2024 as against Rs 74.58 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales89.9274.58 21 OPM %36.7932.05 - PBDT33.7224.07 40 PBT23.9215.64 53 NP21.5010.13 112 Powered by Capital Market - Live News

Vimta Labs will hold a meeting of the Board of Directors of the Company on 24 January 2025.Powered by Capital Market - Live News

Net profit of Vimta Labs rose 140.92% to Rs 15.25 crore in the quarter ended September 2024 as against Rs 6.33 crore during the previous quarter ended September 2023. Sales rose 29.30% to Rs 84.74 crore in the quarter ended September 2024 as against Rs 65.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales84.7465.54 29 OPM %35.3026.56 - PBDT30.1818.84 60 PBT21.8910.19 115 NP15.256.33 141 Powered by Capital Market - Live News

Vimta Labs will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live News

Vimta Labs has completed the sale and transfer of its diagnostic and pathological services business as a going concern to Thyrocare Technologies on 11 October 2024. Powered by Capital Market - Live News